Overview  Founded in 2008  Privately held technology development company  Reorganized under new ownership as Tamarisk Technologies Group in 2014 About Us

Cost effectively increasing the oral bioavailability of existing and emerging drug technologies through better drug delivery design. Tamarisk’s Value Statement to the Pharmaceutical Industry

Our drug carrier platform utilizes an alginate particle substrate engineered to provide targeted GI delivery. Additional on-board attributes can be added to provide subtle manipulation of targeted local environmental parameters to specifically preserve payload drug activity and energize absorption pathways for increased bioavailability. MxBA TM Delivery System Tamarisk’s Technology

 Oral ingestion is generally viewed by most clinicians as the ideal delivery method and lowers the barriers for patient compliance.  Tamarisk Technologies Group has developed a patent pending oral delivery system that microencapsulates therapeutic agents within a protective substrate that can also contain customizable absorption enhancement agents, such as hydrophobic/hydrophilic stabilizers, receptor ligands, permeation enhancers, excipients, or particle enhancements, such as to optimize particle size and/or solid dispersion. MxBA TM Delivery System Enhanced Oral Delivery

Resistant to gastric disintegration Targeted release of the therapeutic payload within the GI tract Capitalizes on multiple features of the local GI environment for assisted entry into the bloodstream Provides increased bioavailability of therapeutic payload Reduced GI induced drug degradation Concentrates actives at desired point of absorption Balances the physiochemical properties of the delivery platform to support optimal transport across the epithelia MxBA TM Delivery System Benefits

MxBA TM Delivery System Tamarisk’s Particle

Therapeutic agents successfully encapsulated include:  Ceftriaxone Sodium (Rocephrin) - showed 73% bioavailability in rabbits  Insulin – In vitro tests showed survival in SGF and good elution profile in SIF. Rat enterocyte cell culture tests demonstrated enhanced transport.  Resveratrol – In vivo tests in rats demonstrated significantly shorter T max with increased C max and AUC compared to controls. * Note: A complete listing of therapeutic agents encapsulated to date is available upon request. MxBA TM Delivery System Results

We believe Tamarisk’s novel particle design is not only an effective solution for various therapeutics we have successfully encapsulated but is the ideal solution as a broad-spectrum platform for orally delivering the most challenging APIs in the industry. MxBA TM Delivery System Results Small Molecules Peptides Proteins Other Functional Molecules Cyclic Peptides Monoclonal antibodies

 Study conducted by Charles River (Wilmington, MA)  Sprague Dawley Rats  Oral administration  Single dose study Mean unencapsulated Resveratrol (20 mg/ml dose) Tamarisk MxBA encapsulated Resveratrol (20 mg/ml dose) Change AUC 0-t ng*h/mL X increase C max ng*h/mL X increase t max h hr faster MxBA TM Delivery System Resveratrol Pre-Clinical Results

Partnering Opportunity Tamarisk's unique delivery platform is ready to be entrusted to an effective global leader in the Healthcare industry who's expertise and core values may be combined with our technology to provide the next generation of leading edge therapeutic products. If your company is looking for the most effective oral delivery system for it's existing pharmaceutical therapies or those in it's pipeline, it's time to consider a new solution. It's time to consider Tamarisk. There's no better time than now for a technology with so much potential to make the world a better place both for us now and for generations to come.

Tamarisk’s MxBA TM Delivery System opens new avenues of development for new drug technologies in the 21 st century. Let Tamarisk custom design a delivery experience for you that is second to none.  Proof of concept test samples can be readily manufactured  No additional complex synthesis  High encapsulation efficiency  Biologic or small molecule capable  Hydrophobic or hydrophilic APIs  Lab-scale operation ready to go  Analytical testing and method development services available MxBA TM Delivery System Next Steps

Meet The Team Dean Crowell | Executive Director John Connell | Chairman/Director of Corp Development A.T. Snoots, II | Director, Operations Darrell Turner | Director, Finance Who We Are

Tamarisk Technologies Group © 2015 All Rights Reserved. No part of this presentation may be copied, modified, printed, or presented without the author’s permission. #NoMoreNeedles

Visit us online at